Protalix BioTherapeutics Names SVP and CFO

Protalix BioTherapeutics Inc., a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins, has appointed Gilad Mamlok as Senior Vice President and Chief Financial Officer, effective August 24, 2025, succeeding Eyal Rubin.

To ensure a seamless transition, Mamlok has joined the company and is working alongside Rubin. After his tenure as Chief Financial Officer concludes, Rubin will remain available to the company as needed until October 2025.

“With his three decades of experience in healthcare and technology companies, Gilad will play a pivotal role in the execution of our growth strategy, and I am delighted to welcome him to the Protalix team,” said Dror Bashan, Protalix’s President and Chief Executive Officer. “I also want to thank Mr. Rubin, both personally and on behalf of Protalix and its Board of Directors, for his unwavering dedication and leadership.”

About Gilad Mamlok

Mamlok is a seasoned financial executive with three decades of experience in healthcare and technology companies. He has an extensive background in capital markets transactions, mergers and acquisitions, business development and investor relations as well as in corporate governance matters.

Most recently, he served as the Chief Financial Officer of TytoCare Ltd., a privately-held company in the remote healthcare space. Prior to his role at TytoCare, Mamlok served as the Chief Financial Officer of Sol-Gel Technologies Ltd. Before that, he served in other medical device companies, including Given Imaging which was acquired by Covidien plc in 2014.

Mamlok holds a BA in Economics, magna cum laude, and a Master’s degree in Business/Managerial Economics, both from the Tel Aviv University.